DNQX

DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) [1].

Product Specifications

CAS Number

[2379-57-9]

Product Name Alternative

FG 9041

UNSPSC

12352005

Hazard Statement

H228, H301+H311+H331, H315, H319

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/DNQX.html

Purity

99.26

Solubility

DMSO : ≥ 35 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C(NC2=CC([N+]([O-])=O)=C([N+]([O-])=O)C=C2N1)=O

Molecular Formula

C8H4N4O6

Molecular Weight

252.14

Precautions

H228, H301+H311+H331, H315, H319

References & Citations

[1]Honoré T, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 1988;241 (4866) :701-703.|[2]Lee SH, et al. Selective excitatory actions of DNQX and CNQX in rat thalamic neurons. J Neurophysiol. 2010;103 (4) :1728-1734.|[3]Sharp JW, et al. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995;687 (1-2) :114-124.